PMID- 31659109
OWN - NLM
STAT- MEDLINE
DCOM- 20200311
LR  - 20200311
IS  - 1790-6245 (Electronic)
IS  - 1109-6535 (Print)
IS  - 1109-6535 (Linking)
VI  - 16
IP  - 6
DP  - 2019 Nov-Dec
TI  - Genetic Characterization of Myoid Hamartoma of the Breast.
PG  - 563-568
LID - 10.21873/cgp.20158 [doi]
AB  - BACKGROUND/AIM: Myoid hamartoma of the breast is a very rare benign lesion of 
      which only a few cases have been reported. The pathogenesis is unknown and 
      nothing is known about its genetic constitution. We report here the genetic 
      characterization of a myoid hamartoma of the breast. MATERIALS AND METHODS: 
      Cytogenetic, fluorescence in situ hybridization (FISH), RNA sequencing, reverse 
      transcription polymerase chain reaction (RT-PCR), and Sanger sequencing analyses 
      were performed on a myoid hamartoma of the breast. RESULTS: G-Banding analysis of 
      short-term cultured tumor cells yielded the karyotype 
      46,XX,t(5;12)(p13;q14)[6]/46,XX[4]. FISH showed rearrangement of the high 
      mobility group AT-hook 2 (HMGA2) gene. RNA sequencing detected fusion of HMGA2 
      (12q14) with a sequence from 5p13. RT-PCR together with Sanger sequencing 
      verified the HMGA2-fusion transcript. CONCLUSION: Myoid hamartoma of the breast 
      may be pathogenetically related to benign connective tissue tumors with HMGA2 
      rearrangements, such as pulmonary hamartomas, lipomas, myolipomas, and 
      leiomyomas.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Panagopoulos, Ioannis
AU  - Panagopoulos I
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway 
      ioannis.panagopoulos@rr-research.no.
FAU - Gorunova, Ludmila
AU  - Gorunova L
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
FAU - Andersen, Hege Kilen
AU  - Andersen HK
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
FAU - Pedersen, Thomas Dahl
AU  - Pedersen TD
AD  - Department of Pathology, Oslo University Hospital, Oslo, Norway.
FAU - Lomo, Jon
AU  - Lomo J
AD  - Department of Pathology, Oslo University Hospital, Oslo, Norway.
FAU - Lund-Iversen, Marius
AU  - Lund-Iversen M
AD  - Department of Pathology, Oslo University Hospital, Oslo, Norway.
FAU - Micci, Francesca
AU  - Micci F
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
FAU - Heim, Sverre
AU  - Heim S
AD  - Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, 
      The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
AD  - Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 
      Norway.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Greece
TA  - Cancer Genomics Proteomics
JT  - Cancer genomics & proteomics
JID - 101188791
RN  - 0 (HMGA2 Protein)
RN  - 0 (HMGA2 protein, human)
SB  - IM
MH  - *Abnormal Karyotype
MH  - Breast Neoplasms/*genetics/pathology
MH  - Chromosomes, Human/*genetics
MH  - Female
MH  - HMGA2 Protein/*genetics
MH  - Hamartoma/*genetics/pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
PMC - PMC6885368
OTO - NOTNLM
OT  - HMGA2 rearrangement
OT  - Myoid hamartoma of the breast
OT  - RNA sequencing
OT  - Sanger sequencing
OT  - chromosome translocation
OT  - cytogenetics
OT  - fluorescence in situ hybridization
OT  - reverse transcription polymerase chain reaction
COIS- The authors declare that they have no potential conflicts of interest in regard 
      to this study.
EDAT- 2019/10/30 06:00
MHDA- 2020/03/12 06:00
PMCR- 2019/11/03
CRDT- 2019/10/30 06:00
PHST- 2019/08/31 00:00 [received]
PHST- 2019/09/23 00:00 [revised]
PHST- 2019/09/26 00:00 [accepted]
PHST- 2019/10/30 06:00 [entrez]
PHST- 2019/10/30 06:00 [pubmed]
PHST- 2020/03/12 06:00 [medline]
PHST- 2019/11/03 00:00 [pmc-release]
AID - 16/6/563 [pii]
AID - 10.21873/cgp.20158 [doi]
PST - ppublish
SO  - Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):563-568. doi: 10.21873/cgp.20158.